Full Breakdown
NHS Trials Innovative Treatment for Acute-on-Chronic Liver Failure
12/21/2025, 11:57:23 AM
Overview of the Trial
The National Health Service (NHS) in the UK is set to conduct a trial for a new treatment aimed at addressing acute-on-chronic liver failure (ACLF), a severe condition that can lead to multiple organ failure and high mortality rates. Thirteen major hospitals will participate in the trial, utilizing a device known as Dialive, which cleanses the blood of toxins that accumulate due to liver dysfunction. The trial will involve 72 patients who are already experiencing multi-organ failure, with the aim of demonstrating improved survival rates compared to standard care.
Background on Acute-on-Chronic Liver Failure
ACLF is a critical and often life-threatening condition that arises from chronic liver disease, commonly linked to obesity, alcohol consumption, and hepatitis infections. The disease is particularly dangerous, with approximately 70% of patients dying within 28 days of diagnosis. Current treatment options are limited, with liver transplantation being the only definitive solution, but only a small fraction of patients qualify for this procedure.
Mechanism of the Dialive Device
Dialive operates similarly to kidney dialysis, removing dysfunctional albumin from the blood and replacing it with functional albumin. This process aims to alleviate the toxic burden on the liver, allowing it to regenerate and potentially reversing the condition. Rajiv Jalan, a senior liver specialist and co-principal investigator of the trial, emphasized the urgent need for effective treatments for ACLF, stating, “These are gravely ill patients with multi-organ failure and high risk of death.”
Funding and Previous Research
The trial, funded by the National Institute for Health and Care Research (NIHR) at a cost of £2.2 million, follows promising results from a smaller study conducted in 2023. In that study, 10 out of 15 patients treated with Dialive showed reversal of ACLF, compared to only five in the control group. Dr. Rohit Saha, another co-principal investigator, noted that Dialive could potentially break the cycle of inflammation that often leads to patient mortality.
Implications for Patient Care
If successful, Dialive could significantly alter the treatment landscape for ACLF, reducing the need for liver transplants and improving patient outcomes. Prof. Mike Lewis, NIHR's scientific director for innovation, remarked on the potential life-saving benefits of the device, stating, “If this NIHR-funded trial of Dialive is successful, it will bring dramatic benefits for patients, providing a treatment for ACLF that will save lives and reduce hospital stay.”
Criticism and Concerns
While the trial represents a hopeful advancement in liver disease treatment, some experts caution about the broader implications of relying on new technologies in healthcare. Concerns have been raised regarding the accessibility of such treatments and the potential for disparities in patient care.
What's Next
The trial is scheduled to commence early next year, with hospitals including King’s College and University College London leading the recruitment of participants. The outcomes of this trial could pave the way for a new standard of care for patients suffering from ACLF, potentially changing the prognosis for thousands affected by this condition.
